Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Senior Vice President | February 15, 2013 | February 20, 2013 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 15, 2013 · Filed February 20, 2013
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 33,000 |
Reported balance
After 2013-02-15 transaction · row 1
1 source rowRow 1 · 2013-02-15 · Grant · Acquired 23,000 · Balance 33,000 F1: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.94 · Expires 2023-02-14 | Direct | 119,700 |
Reported balance
After 2013-02-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2013-02-15 · Grant · Acquired 119,700 · Balance 119,700 F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 39,900 on 2/15/2014, 39,900 on 2/15/2015, and 39,900 on 2/15/2016. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.
F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 39,900 on 2/15/2014, 39,900 on 2/15/2015, and 39,900 on 2/15/2016.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2013 Filed Feb 20, 2013 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 119,700 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-13-003143 · edgar.xml · derivative · entry 2 Magill Paul K · CIK 0001561122 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,700 Underlying: Common shares · 119,700 shares Expires 2023-02-14 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 39,900 on 2/15/2014, 39,900 on 2/15/2015, and 39,900 on 2/15/2016. Read SEC document |
| February 15, 2013 Filed Feb 20, 2013 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-003143 · edgar.xml · nonDerivative · entry 1 Magill Paul K · CIK 0001561122 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| November 01, 2012 Filed Nov 5, 2012 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-015694 · edgar.xml · nonDerivative · entry 1 Magill Paul K · CIK 0001561122 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: These shares represent a retention award of restricted stock under the Abbott Laboratories 2009 Incentive Stock Program. The awards generally vest on the third anniversary of their grant date and include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.